Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Landewé, Robert BM, van der Heijde, Désirée, Dougados, Maxime, Baraliakos, Xenofon, Van den Bosch, Filip E, Gaffney, Karl, Bauer, Lars, Hoepken, Bengt, Davies, Owen R, de Peyrecave, Natasha, Thomas, Karen, Gensler, Lianne
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Spondyloarthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307216/
https://ncbi.nlm.nih.gov/pubmed/32381562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216839
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados